Comparative study of helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump lnhibitor and clarithromycin: A randomized study

Helicobacter

Volumn 13, Issue 4, 2008, Pages 282-287

  Kim, Seung Young ^a   Lee, Sang Woo ^a   Jung, Sung Woo ^a   Koo, Ja Seol ^a   Yim, Hyung Joon ^a   Park, Jong Jae ^a   Chun, Hoon Jai ^a   Lee, Hong Sik ^a   Choi, Jai Hyun ^a   Kim, Chang Duck ^a   Ryu, Ho Sang ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Amoxicillin; Drug administration schedule; Helicobacter pylori

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; PROTON PUMP INHIBITOR;

ABDOMINAL DISCOMFORT; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BITTER TASTE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG ODOR; DRUG SAFETY; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; NAUSEA; ODOR; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; DRUG TOXICITY; KOREA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY;

HELICOBACTER PYLORI;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KOREA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 51049112703     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2008.00615.x     Document Type: Article

References (25)

1. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, Malaty HM. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116:705-8.
2. Korean H. pylori Study Group. Diagnosis and treatment of Helicobacter pylori infection in Korea. Korean J Gastroenterol 1998;32:275-89.
3. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003;98:S31-9.
4. Sivapalasingam S, Steigbigel NH. Macrolides, clindamycin, and ketolides. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Doughlas, and Bennett's Principles and Practice of Infectious Disease, 6th edn. Philadelphia, PA: Elsevier, 2005;396-417.
5. Mouton JW, Vinks AA. Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996;38:5-15.
6. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998;35:391-402.
7. Ronchera-Oms CL, Gregorio S, Sanllehi N. Should continuous infusion of beta-lactam antibiotics be the first-line approach? J Clin Pharm Ther 1997;22:159-61.
8. Chambers HF. Penicillins. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Doughlas, and Bennett's Principles and Practice of Infectious Disease, 6th edn. Philadelphia, PA: Elsevier, 2005;281-93.
9. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007;12:31-5.
10. Queiroz DM, Dani R, Silva LD, et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 2002;35:315-20.
11. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
12. Qasim A, O'Morain CA. Review article. Treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002;16:S24-S30.
13. Vakil N. Helicobacter pylori treatment: a practical approach. Am J Gastroenterol 2006;101:497-9.
14. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;333:984-91.
15. Hoffman A, Danenberg HD, Katzhendler I, Shuval R, Gilhar D, Friedman M. Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form. J Control Release 1998;54:29-37.
16. Midolo PD, Turnidge JD, Munckhof WJ. Is bactericidal activity of amoxicillin against Helicobacter pylori concentration dependent? Antimicrob Agents Chemother 1996;40:1327-8.
17. Amsden GW, Ballow CH, Bertino JS, Kashuba ADM. Pharmacokinetics and pharmacodynamics of anti-infective agents. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Doughlas, and Bennett's Principles and Practice of Infectious Disease, 6th edn. Philadelphia, PA: Elsevier, 2005;271-80.
18. Nakamura M, Spiller RC, Barrett DA, Wibawa JI, Kumagai N, Tsuchimoto K, Tanaka T. Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter 2003;8:294-9.
19. Keum BR, Lee SW, Kim SY, et al. Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy. Korean J Gastroenterol 2005;46:433-9.
20. Choi YS, Cheon JH, Lee JY, Kim SG, Kim JS, Kim N, Lee DH, Kim JM, Jung HC, Song IS. The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years. Korean J Gastroenterol 2006;48:156-61.
21. Na HS, Hong SJ, Yoon HJ, et al. Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication. Korean J Gastroenterol 2007;50:170-5.
22. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ, Klein PD, Alpert LC, Genta RM. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.
23. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxicillin, clarithromycin and metronidazole in gastric juice; relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997;39:5-12.
24. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004;48:4843-7.
25. Kim N, Kim JM, Kim CH, Park YS, Lee DH, Kim JS, Jung HC, Song IS. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 2006;40:683-7.